Research programme: prostaglandin D2 receptor antagonists - Ligand Pharmaceuticals

Drug Profile

Research programme: prostaglandin D2 receptor antagonists - Ligand Pharmaceuticals

Alternative Names: CRTH2 Antagonist - Ligand Pharmaceuticals

Latest Information Update: 28 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ligand Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Allergic rhinitis; Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 22 Sep 2016 Research programme: prostaglandin D2 receptor antagonists - Ligand Pharmaceuticals licensed to Seelos Therapeutics
  • 01 Sep 2015 Prostaglandin D2 receptor antagonists are available for licensing as of 01 Sep 2015. http://www.ligand.com/
  • 01 Sep 2015 Preclinical trials in Allergic rhinitis, Asthma and Chronic obstructive pulmonary disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top